Acute Lung Injury - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acute Lung Injury - Pipeline Review, H2 2016’, provides an overview of the Acute Lung Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury

The report reviews pipeline therapeutics for Acute Lung Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Lung Injury therapeutics and enlists all their major and minor projects

The report assesses Acute Lung Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Lung Injury

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Altor BioScience Corp

Asklepion Pharmaceuticals LLC

Commence Bio Inc

CompleGen Inc

GlaxoSmithKline Plc

Histocell SL

Lung Therapeutics Inc

Navigen Pharmaceuticals Inc

Quark Pharmaceuticals Inc

S-Evans ...

Altor BioScience Corp

Asklepion Pharmaceuticals LLC

Commence Bio Inc

CompleGen Inc

GlaxoSmithKline Plc

Histocell SL

Lung Therapeutics Inc

Navigen Pharmaceuticals Inc

Quark Pharmaceuticals Inc

S-Evans Biosciences Inc

Silence Therapeutics Plc

Stemedica Cell Technologies Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acute Lung ...

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acute Lung Injury Overview 10

Therapeutics Development 11

Pipeline Products for Acute Lung Injury - Overview 11

Pipeline Products for Acute Lung Injury - Comparative Analysis 12

Acute Lung Injury - Therapeutics under Development by Companies 13

Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15

Acute Lung Injury - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Acute Lung Injury - Products under Development by Companies 19

Acute Lung Injury - Products under Investigation by Universities/Institutes 21

Acute Lung Injury - Companies Involved in Therapeutics Development 22

Altor BioScience Corp 22

Asklepion Pharmaceuticals LLC 23

Commence Bio Inc 24

CompleGen Inc 25

GlaxoSmithKline Plc 26

Histocell SL 27

Lung Therapeutics Inc 28

Navigen Pharmaceuticals Inc 29

Quark Pharmaceuticals Inc 30

S-Evans Biosciences Inc 31

Silence Therapeutics Plc 32

Stemedica Cell Technologies Inc 33

Acute Lung Injury - Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

ALT-836 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Atu-111 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

BC-1215 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BIO-10901 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CGX-1037 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CMB-200 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

EC-18 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

FAB-117HC - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

GSK-2586881 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

GSK-2862277 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

L-Citrulline - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

LTI-02 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

MG-53 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

NAV-2729 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

P- BEFizumab - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

QPLI-2 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

R-10001 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

R-107 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

R-901 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

R-911 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Recombinant Proteins for Acute Lung Injury - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

S-1229 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Stem Cell Therapy for Acute Lung Injury - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

TXA-302 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Acute Lung Injury - Dormant Projects 89

Acute Lung Injury - Discontinued Products 92

Acute Lung Injury - Product Development Milestones 93

Featured News & Press Releases 93

Mar 03, 2015: Navigen Announces Phase I NIH SBIR Award to support the Development of ARF6 Inhibitors to Treat Acute Lung Injury/Acute Respiratory Distress 93

Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 93

Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 94

Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 94

May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Tables

List of Tables

Number of Products under Development for Acute Lung Injury, H2 2016 11

Number of Products under Development for Acute Lung Injury - ...

List of Tables

Number of Products under Development for Acute Lung Injury, H2 2016 11

Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Acute Lung Injury - Pipeline by Altor BioScience Corp, H2 2016 22

Acute Lung Injury - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 23

Acute Lung Injury - Pipeline by Commence Bio Inc, H2 2016 24

Acute Lung Injury - Pipeline by CompleGen Inc, H2 2016 25

Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2016 26

Acute Lung Injury - Pipeline by Histocell SL, H2 2016 27

Acute Lung Injury - Pipeline by Lung Therapeutics Inc, H2 2016 28

Acute Lung Injury - Pipeline by Navigen Pharmaceuticals Inc, H2 2016 29

Acute Lung Injury - Pipeline by Quark Pharmaceuticals Inc, H2 2016 30

Acute Lung Injury - Pipeline by S-Evans Biosciences Inc, H2 2016 31

Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2016 32

Acute Lung Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016 33

Assessment by Monotherapy Products, H2 2016 34

Number of Products by Stage and Target, H2 2016 36

Number of Products by Stage and Mechanism of Action, H2 2016 38

Number of Products by Stage and Route of Administration, H2 2016 40

Number of Products by Stage and Molecule Type, H2 2016 42

Acute Lung Injury - Dormant Projects, H2 2016 89

Acute Lung Injury - Dormant Projects (Contd..1), H2 2016 90

Acute Lung Injury - Dormant Projects (Contd..2), H2 2016 91

Acute Lung Injury - Discontinued Products, H2 2016 92

List of Figures

List of Figures

Number of Products under Development for Acute Lung Injury, H2 2016 11

Number of Products under Development for Acute Lung Injury - ...

List of Figures

Number of Products under Development for Acute Lung Injury, H2 2016 11

Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 34

Number of Products by Top 10 Targets, H2 2016 35

Number of Products by Stage and Top 10 Targets, H2 2016 35

Number of Products by Top 10 Mechanism of Actions, H2 2016 37

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 37

Number of Products by Routes of Administration, H2 2016 39

Number of Products by Stage and Routes of Administration, H2 2016 39

Number of Products by Top 10 Molecule Types, H2 2016 41

Number of Products by Stage and Top 10 Molecule Types, H2 2016 41

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports